Literature DB >> 15542983

Epilepsy after head injury.

Raimondo D'Ambrosio1, Emilio Perucca.   

Abstract

PURPOSE OF REVIEW: The purpose of this short review is to provide an update on the epidemiology of posttraumatic epilepsy, associated risk factors, data from prevention studies, and recent breakthroughs in experimental research. RECENT
FINDINGS: There is increasing evidence that neuroimaging findings, stratification by neurosurgical procedures performed, and genomic information (e.g. apolipoprotein E and haptoglobin genotypes) may provide useful predictors of the individual risk of developing posttraumatic epilepsy. While antiepileptic drug prophylaxis can be effective in protecting against acute (provoked) seizures occurring within 7 days after injury, no antiepileptic drug treatment has been found to protect against the development of posttraumatic epilepsy and therefore long-term anticonvulsant prophylaxis is not recommended. Glucocorticoid administration early after head injury also has not been found to reduce the risk of posttraumatic epilepsy. At the basic research level, there have been advances in the understanding of pathophysiological changes in posttraumatic excitatory and inhibitory synapses, and the critical period for epileptogenesis after head injury has been better defined. Finally, the development of a novel animal model, which mimicks more closely human posttraumatic epilepsy, may facilitate efforts to characterize relevant epileptogenic mechanisms and to identify clinically effective antiepileptogenic treatments.
SUMMARY: Despite the continuing lack of clinically effective agents for posttraumatic epilepsy prophylaxis, recent advances in basic and clinical research offer new hope for success in the development of new strategies for prevention and treatment.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15542983      PMCID: PMC2672045          DOI: 10.1097/00019052-200412000-00014

Source DB:  PubMed          Journal:  Curr Opin Neurol        ISSN: 1350-7540            Impact factor:   5.710


  35 in total

1.  Posttraumatic epilepsy: neuroradiologic and neuropsychological assessment of long-term outcome.

Authors:  Letizia Mazzini; Federico Maria Cossa; Elisabetta Angelino; Riccardo Campini; Ilaria Pastore; Francesco Monaco
Journal:  Epilepsia       Date:  2003-04       Impact factor: 5.864

Review 2.  Animal models of epileptogenesis.

Authors:  H Steve White
Journal:  Neurology       Date:  2002-11-12       Impact factor: 9.910

Review 3.  Models for epilepsy and epileptogenesis: report from the NIH workshop, Bethesda, Maryland.

Authors:  James P Stables; Edward H Bertram; H Steve White; Douglas A Coulter; Marc A Dichter; Margaret P Jacobs; Wolfgang Loscher; Daniel H Lowenstein; Solomon L Moshe; Jeffrey L Noebels; Mirian Davis
Journal:  Epilepsia       Date:  2002-11       Impact factor: 5.864

4.  Magnetization transfer MR imaging in patients with posttraumatic epilepsy.

Authors:  Rajesh Kumar; Rakesh K Gupta; Mazhar Husain; Davender K Vatsal; Sanjeev Chawla; Ram Kishore S Rathore; Sunil Pradhan
Journal:  AJNR Am J Neuroradiol       Date:  2003-02       Impact factor: 3.825

Review 5.  Genetic vulnerability following traumatic brain injury: the role of apolipoprotein E.

Authors:  N Nathoo; R Chetty; J R van Dellen; G H Barnett
Journal:  Mol Pathol       Date:  2003-06

6.  Increased risk of late posttraumatic seizures associated with inheritance of APOE epsilon4 allele.

Authors:  Ramon Diaz-Arrastia; Yunhua Gong; Suzette Fair; Kristin D Scott; Maria C Garcia; Mary C Carlile; Mark A Agostini; Paul C Van Ness
Journal:  Arch Neurol       Date:  2003-06

7.  Analyzing risk factors for late posttraumatic seizures: a prospective, multicenter investigation.

Authors:  Jeffrey Englander; Tamara Bushnik; Thao T Duong; David X Cifu; Ross Zafonte; Jerry Wright; Richard Hughes; William Bergman
Journal:  Arch Phys Med Rehabil       Date:  2003-03       Impact factor: 3.966

Review 8.  Practice parameter: antiepileptic drug prophylaxis in severe traumatic brain injury: report of the Quality Standards Subcommittee of the American Academy of Neurology.

Authors:  Bernard S Chang; Daniel H Lowenstein
Journal:  Neurology       Date:  2003-01-14       Impact factor: 9.910

Review 9.  New strategies for the identification of drugs to prevent the development or progression of epilepsy.

Authors:  Dieter Schmidt; Michael A Rogawski
Journal:  Epilepsy Res       Date:  2002-06       Impact factor: 3.045

Review 10.  Animal models of epilepsy for the development of antiepileptogenic and disease-modifying drugs. A comparison of the pharmacology of kindling and post-status epilepticus models of temporal lobe epilepsy.

Authors:  Wolfgang Löscher
Journal:  Epilepsy Res       Date:  2002-06       Impact factor: 3.045

View more
  31 in total

1.  Recovery of motor deficit, cerebellar serotonin and lipid peroxidation levels in the cortex of injured rats.

Authors:  Antonio Bueno-Nava; Rigoberto Gonzalez-Pina; Alfonso Alfaro-Rodriguez; Vladimir Nekrassov-Protasova; Alfredo Durand-Rivera; Sergio Montes; Fructuoso Ayala-Guerrero
Journal:  Neurochem Res       Date:  2010-06-10       Impact factor: 3.996

2.  Focal transient lesion in the splenium of the corpus callosum in three non-epileptic patients.

Authors:  Antônio José da Rocha; Fabiano Reis; Hugo Pereira Pinto Gama; Carlos Jorge da Silva; Flávio Túlio Braga; Antônio Carlos Martins Maia; Fernando Cendes
Journal:  Neuroradiology       Date:  2006-08-30       Impact factor: 2.804

3.  Development of a novel therapeutic suppressor of brain proinflammatory cytokine up-regulation that attenuates synaptic dysfunction and behavioral deficits.

Authors:  Wenhui Hu; Hantamalala Ralay Ranaivo; Saktimayee M Roy; Heather A Behanna; Laura K Wing; Lenka Munoz; Ling Guo; Linda J Van Eldik; D Martin Watterson
Journal:  Bioorg Med Chem Lett       Date:  2006-10-17       Impact factor: 2.823

Review 4.  Combination therapies for neurobehavioral and cognitive recovery after experimental traumatic brain injury: Is more better?

Authors:  Anthony E Kline; Jacob B Leary; Hannah L Radabaugh; Jeffrey P Cheng; Corina O Bondi
Journal:  Prog Neurobiol       Date:  2016-05-07       Impact factor: 11.685

5.  Astrocytes: Stars of the Sacred Disease.

Authors:  Devin K Binder
Journal:  Epilepsy Curr       Date:  2018 May-Jun       Impact factor: 7.500

6.  Minozac treatment prevents increased seizure susceptibility in a mouse "two-hit" model of closed skull traumatic brain injury and electroconvulsive shock-induced seizures.

Authors:  MaryAnn Chrzaszcz; Charu Venkatesan; Tina Dragisic; D Martin Watterson; Mark S Wainwright
Journal:  J Neurotrauma       Date:  2010-07       Impact factor: 5.269

7.  Functional definition of seizure provides new insight into post-traumatic epileptogenesis.

Authors:  Raimondo D'Ambrosio; Shahin Hakimian; Tessandra Stewart; Derek R Verley; Jason S Fender; Clifford L Eastman; Aaron H Sheerin; Puneet Gupta; Ramon Diaz-Arrastia; Jeffrey Ojemann; John W Miller
Journal:  Brain       Date:  2009-09-15       Impact factor: 13.501

8.  Chronic upregulation of activated microglia immunoreactive for galectin-3/Mac-2 and nerve growth factor following diffuse axonal injury.

Authors:  Charu Venkatesan; MaryAnn Chrzaszcz; Nicole Choi; Mark S Wainwright
Journal:  J Neuroinflammation       Date:  2010-05-27       Impact factor: 8.322

9.  Can structural or functional changes following traumatic brain injury in the rat predict epileptic outcome?

Authors:  Sandy R Shultz; Lisa Cardamone; Ying R Liu; R Edward Hogan; Luigi Maccotta; David K Wright; Ping Zheng; Amelia Koe; Marie-Claude Gregoire; John P Williams; Rodney J Hicks; Nigel C Jones; Damian E Myers; Terence J O'Brien; Viviane Bouilleret
Journal:  Epilepsia       Date:  2013-05-29       Impact factor: 5.864

10.  NNZ-2566 treatment inhibits neuroinflammation and pro-inflammatory cytokine expression induced by experimental penetrating ballistic-like brain injury in rats.

Authors:  Hans H Wei; Xi-Chun M Lu; Deborah A Shear; Anu Waghray; Changping Yao; Frank C Tortella; Jitendra R Dave
Journal:  J Neuroinflammation       Date:  2009-08-05       Impact factor: 8.322

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.